Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
From outside firms

Analysis and Perspectives

Commentary and analysis from outside consulting and policy firms. Not part of Medicaid Monitor's independently scored news coverage. Each piece links back to the firm's original publication.

Avalere · Oct 30

2027 Medicare Advantage Supplemental Benefits Vary Sharply by Plan Type, Including Dual-Eligible Plans

Avalere's analysis compares 2027 Medicare Advantage supplemental benefit offerings across non-SNPs, Chronic Condition Special Needs Plans, and Dual Eligible Special Needs Plans (D-SNPs), finding that transportation, meal, and nutrition benefits vary considerably by plan type. D-SNPs, which serve Medicaid-Medicare dual eligibles, will offer the highest rates of transportation (66.2%) and meal benefits (68.2%), while C-SNPs saw declines in these same benefits compared to 2026. For Medicaid managed care stakeholders, these trends matter because D-SNP benefit design directly affects care coordination and supplemental services for the dually eligible population many MCOs serve.

Read at avalerehealth.com →
Avalere · Oct 26

CMS's 340B Payment Proposal Could Squeeze Hospitals on High-Cost Drugs, With Medicaid Rebate Ties

The analysis examines CMS's proposed CY2027 OPPS rule to reimburse 340B drugs at ASP minus 33.4%, showing that this flat benchmark may not match actual acquisition costs across therapeutic classes, with some drug categories facing underpayment relative to real costs. It notes how 340B ceiling prices are calculated using Medicaid Average Manufacturer Price and rebate amounts, meaning deeper Medicaid rebates can push 340B prices even lower, creating ripple effects relevant to drug pricing and rebate policy that touch Medicaid programs indirectly.

avalerehealth.com →
Avalere · Sep 18

USPSTF Reconstituted with More Specialists After Year-Long Hiatus, Raising Coverage Policy Questions for Plans

HHS has appointed eight new members to the U.S. Preventive Services Task Force after more than a year of inactivity, restoring the panel to 16 members with a notably different composition that includes more specialists and fewer primary care physicians. The reconstitution matters for Medicaid managed care because USPSTF recommendations with A or B grades trigger mandatory coverage without cost-sharing under the ACA, affecting benefit design, utilization management, and preventive service demand across health plans. The panel's new makeup and potential shifts in evidence review approaches could influence future preventive care coverage requirements.

advisory.avalerehealth.com →
Avalere · Sep 15

CMS Proposes State-Specific Provider Tax Caps with Major Budget Impact, Including New Health Insurer Tax Class

CMS has proposed implementing the OBBBA's provider tax changes with significant new details: state-specific thresholds based on taxes in place as of July 2025, a zero-percent threshold for new tax classes, exemptions for non-expansion states and certain facility types, and elimination of the 75/75 workaround pathway. The rule would reduce federal Medicaid spending by $246 billion over ten years—substantially more than originally estimated—forcing states and MCOs to fundamentally rethink Medicaid financing strategies. The proposal also introduces health insurers as a newly permissible tax class, directly affecting managed care plan operations and rate structures.

advisory.avalerehealth.com →
Avalere · Sep 2

Major Medicaid MCOs Face Margin Pressure from High Acuity Members and State Rate Uncertainty

Analysis of Q2 2026 earnings from six major publicly traded health plans shows Medicaid managed care operations are under financial strain due to higher-than-expected member acuity and uncertainty around state payment rates and policy changes including redeterminations and work requirements. Unlike Medicare Advantage where plans are prioritizing profitability over growth, Medicaid MCOs remain heavily dependent on state rate adequacy amid ongoing eligibility policy shifts. The findings highlight continuing challenges for Medicaid plan financial sustainability as post-pandemic enrollment dynamics stabilize.

advisory.avalerehealth.com →
Avalere · Aug 11

Avalere Launches Video Series on Medicare Advantage Risk Adjustment, Stars Ratings, and Plan Compliance

Avalere's new explainer video series addresses regulatory changes affecting health plans, with episodes covering Medicare Advantage risk adjustment methodology shifts, the Clover Health Stars lawsuit implications, and heightened federal program integrity enforcement. While focused primarily on Medicare Advantage rather than Medicaid managed care, the compliance and regulatory themes—particularly around fraud, waste, and abuse oversight—have parallel implications for Medicaid MCO operations and state oversight strategies.

advisory.avalerehealth.com →
Avalere · Aug 7

Medicare Drug Price Negotiation Refund Rules Could Create Varying Burdens for Medicaid MCOs Based on Drug Discount Profiles

CMS's proposed standardized refund methodologies under the Medicare Drug Negotiation Program would calculate manufacturer rebates differently depending on whether drugs have deep existing discounts or not, creating varying financial impacts across competitive drug classes. This matters for Medicaid managed care because the Medicare negotiated prices will serve as benchmarks and could reshape manufacturer pricing strategies and discount structures that MCOs rely on for pharmacy benefits. Plans with formularies weighted toward either high-discount or low-discount competitive classes may face different financial exposure as these Medicare pricing policies take effect.

advisory.avalerehealth.com →
Avalere · Aug 4

State Drug Pricing Boards Pivot Toward Medicare-Based Upper Payment Limits as Early Models Stall

State prescription drug affordability boards are increasingly tying their price caps to Medicare negotiated prices rather than developing independent methodologies, with Colorado and Maryland leading this approach for products like Enbrel and Ozempic. However, no upper payment limit has actually taken effect yet, some states have dissolved their boards entirely, and aggressive bills in Virginia have faced repeated vetoes. The shift matters for Medicaid MCOs because these state pricing controls would directly affect pharmacy reimbursement rates and formulary strategies if they ultimately go into effect.

advisory.avalerehealth.com →
Avalere · Jul 14

Navigating the Shifting Landscape of Medicaid Work Requirements

Avalere experts discuss how states and Medicaid health plans should respond to ongoing legal and policy uncertainty surrounding Medicaid work requirements. The commentary offers strategic guidance for navigating implementation amid shifting federal signals, which matters for MCOs and state officials managing eligibility, enrollment, and compliance risk.

avalerehealth.com →
Avalere · Jul 10

State-by-State Variation in Medicaid Work Requirements Creates Compliance Challenges for MCOs

Federal rules implementing January 2027 Medicaid work requirements delegate critical operational decisions to states, including how to define medical frailty exemptions and verify compliance. Early implementation in Nebraska and Montana shows dramatic state variation—from 6,800 qualifying diagnosis codes in one state to fewer than 100 conditions in another—creating complex compliance environments for health plans operating across multiple jurisdictions. MCOs will face differential enrollment impacts, varying administrative burdens, and state-specific verification protocols as they prepare systems for the rollout.

advisory.avalerehealth.com →
Avalere · Jul 9

How Medicaid MCOs Should Prepare for January 2027 Work Requirements and Narrow Medical Frailty Exemptions

CMS's interim final rule on Medicaid work requirements takes effect January 2027, requiring 80 hours monthly of qualifying activities from most non-pregnant working-age adults. The medical frailty exemption is narrower than expected—requiring both a serious condition and impairment in at least one activity of daily living—meaning many chronically ill enrollees may lose coverage. Avalere estimates 7.8 million could become uninsured by 2034, creating urgent operational and care continuity challenges for MCOs serving affected populations.

advisory.avalerehealth.com →
Avalere · Jun 30

New Federal Scrutiny Raises the Bar on Health Plan Program Integrity

Avalere Health experts outline intensifying federal oversight of Fraud, Waste, and Abuse and expanding Program Integrity requirements affecting health plans, including Medicaid MCOs. The commentary flags specific policy shifts compliance teams should monitor now to avoid regulatory exposure, making it directly useful for Medicaid managed care compliance functions.

avalerehealth.com →
Avalere · Jun 23

Preparing for Federal Medicaid Work Requirements: Implementation Strategies for MCOs and State Agencies Ahead of 2027 Deadline

Federal Medicaid work requirements mandating 80 hours monthly of community engagement for expansion adults aged 19-64 take effect January 2027, with states responsible for defining exemptions, compliance pathways, and verification processes. The rule creates significant operational and financial uncertainty for Medicaid managed care plans, which must prepare enrollment systems and work with state agencies on implementation decisions that will vary substantially by jurisdiction. Stakeholders including MCOs should engage now during the comment period and state planning phase to shape exemption policies, hardship provisions, and compliance demonstration approaches that will directly affect coverage continuity and plan operations.

advisory.avalerehealth.com →
Avalere · Jun 15

Managed Care Plans Face January 2027 Deadline as CMS Issues Work Requirement Rule Projecting 15% Disenrollment

CMS's June 2026 interim final rule establishes Medicaid community engagement requirements effective January 2027, applying to non-pregnant adults 19-64 in expansion populations across 43 states and DC. The rule includes a stricter-than-expected medical frailty exemption requiring ADL impairment and prohibits states from delegating eligibility verification to MCOs, while CMS projects combined 15% disenrollment from noncompliance and procedural issues. MCOs must now prepare operational strategies to mitigate enrollment loss and support members in meeting requirements, even as they cannot directly perform eligibility verification.

advisory.avalerehealth.com →
Avalere · May 29

Vaccine Policy Upheaval Forces Medicaid Plans to Navigate Fragmented Immunization Guidance

Federal disruption to ACIP has created challenges for Medicaid managed care organizations as they manage immunization coverage policies amid fragmented guidance from multiple clinical bodies. While a March 2026 injunction preserved broad vaccine coverage requirements, the uncertainty has forced states and health plans to independently maintain coverage policies, creating implementation complexity. The article explores how public health stakeholders are adapting to fill federal policy gaps through alternative recommendation pathways and trust-building efforts.

advisory.avalerehealth.com →
Avalere · Mar 31

Federal Kidney Care Payment Reforms and Transplant Policy Changes Shape 2026 Coverage Landscape

CMS is overhauling kidney care through transplant system modernization, new organ procurement standards, and the mandatory IOTA Model launched in mid-2025, while simultaneously sunsetting underperforming value-based care models like ESRD Treatment Choices. The piece examines how federal payment reforms, emerging xenotransplant technology, and refined Kidney Care Choices models are reshaping the dialysis and transplant ecosystem. While primarily Medicare-focused, these structural changes affect Medicaid managed care plans covering dual-eligible populations and states with integrated care models for members with end-stage renal disease.

advisory.avalerehealth.com →
Avalere · Mar 26

CMS Quality Conference Signals Shift Toward Prevention, Real-Time Measurement, and AI in Medicaid and Medicare Programs

The 2026 CMS Quality Conference outlined major policy directions affecting both Medicare and Medicaid managed care, emphasizing prevention-focused models, technology-enabled whole-person care, real-time quality measurement, and AI integration. CMS leadership signaled that quality strategies will increasingly prioritize upstream preventive interventions and align payment incentives with clinical outcomes, requiring health plans to demonstrate how their programs contribute to prevention and reduce downstream utilization. These emerging federal priorities will shape how Medicaid MCOs structure their quality improvement programs, demonstrate value, and respond to evolving state contract requirements.

advisory.avalerehealth.com →
Avalere · Mar 5

States Shift Away from Bundled Payments for Cell and Gene Therapies to Capture Rebates

Medicaid programs are increasingly moving away from bundled payment methodologies for cell and gene therapies in order to separately identify these drugs and collect manufacturer rebates under the Medicaid Drug Rebate Program. This shift provides more predictable reimbursement for providers but increases rebate exposure for manufacturers. The piece also explores the expansion of CAR-T administration into community outpatient settings and implications for access and reimbursement across payer types.

advisory.avalerehealth.com →
Avalere · Mar 2

States Adjust Medicaid Benefits, Rate Setting, and MCO Procurement in Response to Federal Financing Changes

Avalere examines how state Medicaid programs are responding to budget pressure from the One Big Beautiful Bill Act, new provider tax restrictions, and rising utilization. States are adjusting managed care rates, benefits packages, and procurement timelines to navigate tighter fiscal conditions while managing administrative constraints. The analysis outlines decision-making factors that will shape state actions affecting MCO contracts and payment structures in the current budget cycle.

advisory.avalerehealth.com →
Avalere · Feb 12

Gene Therapy Payment Models Pose Multi-Year Budget Challenge for Payers

Gene therapies for rare diseases create structural tension between one-time treatments with multi-decade outcomes and payer systems built on annual budgets and short-term evidence cycles. With 26 FDA-approved gene therapies now in use and more coming, the piece argues healthcare delivery infrastructure and financing models—not just clinical science—will determine patient access and long-term sustainability. For Medicaid MCOs, this raises questions about payment structures, coverage decisions, and evidence generation obligations for high-cost, one-time interventions.

advisory.avalerehealth.com →

Get the daily briefing.